A patient may have pre-existing antibodies (PEXA) to a therapeutic, which can impact the immune response to the drug in question. In this paper, we discuss the nature of PEXAs, how they can be detected and characterized, and how sponsors should proceed when they are present.

Frontage develops a full validation of the XTMAB-16 NAb (neutralizing antibody) assay with acceptable drug and target tolerances to guide future clinical trials.

Frontage is a global CRO advancing drug discovery and development with a comprehensive portfolio of genomics services. We deliver accurate and in-depth analyses to move compounds through early discovery and preclinical studies and for translational and clinical programs.